Tang Jia, Song Tiantian, Kuang Ming, Liu Hongying
Hangzhou Kang Ming Information Technology Co., Ltd., Hangzhou, China.
Hangzhou Kang Sheng Health Consulting Co., Ltd., Hangzhou, China.
Ther Adv Chronic Dis. 2025 May 14;16:20406223251334439. doi: 10.1177/20406223251334439. eCollection 2025.
In recent decades, the prevalence of dyslipidemia, especially high low-density lipoprotein cholesterol (LDL-C), has risen sharply in China. Although lifestyle interventions are important, traditional face-to-face approaches have limitations. Digital Therapeutics (DTx) can provide an effective solution by delivering remote medical interventions to patients via software and hardware, thereby optimizing existing clinical treatment methods with enhanced convenience and accessibility.
This study aims to explore the current evidence on the effect of lifestyle intervention-based Digital Therapeutics (LI-DTx) on high LDL-C, and to analyze their advantages and disadvantages.
This scoping review examines clinical studies assessing the effects of DTx on LDL-C levels. Papers were included in the final analysis if there was evidence that DTx had effects on lowering LDL-C levels.
Papers that were published between January 2014 and December 2023 were included in the PubMed database.
Data extracted from the publications included country, year, study type, study population, sample size, study duration, intervention, and changes in LDL-C level.
A total of 23 target literature were identified. Twenty-one studies confirmed that LI-DTx could optimize the LDL-C level through remote lifestyle interventions such as diet, exercise, medication, and health education, of which 14 studies reported a significant reduction in LDL-C level ( < 0.05). In the future, the development and design of DTx will need to improve intelligence, personalization, applicability, real-time performance, and data security; integrate with traditional healthcare systems; facilitate multidisciplinary collaboration in dyslipidemia management; and enhance long-term patient engagement with DTx platforms.
LI-DTx may offer a more effective and sustainable solution for LDL-C management, although several challenges remain. Further randomized controlled clinical trials are needed to provide scientific support for its efficacy and safety.
近几十年来，中国血脂异常的患病率急剧上升，尤其是高低密度脂蛋白胆固醇（LDL-C）。尽管生活方式干预很重要，但传统的面对面方式存在局限性。数字疗法（DTx）可以通过软件和硬件为患者提供远程医疗干预，从而提供有效的解决方案，以增强便利性和可及性来优化现有的临床治疗方法。
本研究旨在探讨基于生活方式干预的数字疗法（LI-DTx）对高LDL-C影响的现有证据，并分析其优缺点。
本范围综述审查评估DTx对LDL-C水平影响的临床研究。如果有证据表明DTx对降低LDL-C水平有影响，则将论文纳入最终分析。
2014年1月至2023年12月期间发表的论文纳入PubMed数据库。
从出版物中提取的数据包括国家、年份、研究类型、研究人群、样本量、研究持续时间、干预措施以及LDL-C水平的变化。
共确定了23篇目标文献。21项研究证实，LI-DTx可以通过饮食、运动、药物治疗和健康教育等远程生活方式干预来优化LDL-C水平，其中14项研究报告LDL-C水平显著降低（<0.05）。未来，DTx的开发和设计需要提高智能性、个性化、适用性、实时性和数据安全性；与传统医疗系统整合；促进血脂异常管理中的多学科协作；并增强患者对DTx平台的长期参与度。
LI-DTx可能为LDL-C管理提供更有效和可持续的解决方案，尽管仍存在一些挑战。需要进一步的随机对照临床试验为其疗效和安全性提供科学支持。
